Skip to content
Politically.com Search all
Menu

2026 · 2nd Quarter (Apr 1 - June 30)

ALKERMES, INC.

Filed by LMH STRATEGIC SOLUTIONS.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 5, 2026
Income
$60,000.00
Expenses
Not reported
Filing UUID
29a1f11a-d0e7-457c-90c9-e999a1ff4b84
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Medicare/Medicaid issues. Medicaid drug rebate program. Prescription drug pricing, including MDRP Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. H.R.946: ORPHAN Cures Act. Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically. Provide guidance and advice regarding mental health, public health and regulatory reform.

Literal federal measure citations: H.R.946

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.